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Abstract Kynureninase |E.C.3.7.1.3.| is one of the enzymes 
involved in the biosynthesis of NAD cofactors from tryptophan 
through the kynurenine pathway. By tryptic and CNBr digestion 
of purified rat liver kynureninase, we obtained about 28% of the 
ammo acid sequence of the enzyme. The rat kynureninase cDNA, 
isolated by means of reverse-transcribed polymerase chain 
reaction and hybridization screening, codes for a polypeptide of 
464 amino acids. Northern blot analysis revealed the synthesis of 
a 2.0 kb rat kynureninase mRNA. A cDNA encoding human liver 
kynureninase was also isolated. The deduced amino acid 
sequence is 85% identical to that of the rat protein. COS-1 cells 
were transfected with both cDNAs. The An, values of the rat 
enzyme, for L-kynurenine and DL-3-hydroxykynurenine, were 
440 ± 20 μΜ and 32 ± 5 uM and of the human enzyme 440 ± 20 
μΜ and 49 ±6 uM, respectively. Interestingly, COS-1 cells 
transfected with the cDNA coding for rat kynureninase also 
display cysteine-conjugate ß-lyase activity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Kynureninase [L-kynurenine hydrolase E.C.3.7.1.3] cata-
lyzes the conversion of L-3-hydroxykynurenine (3-OHKYN) 
and L-kynurenine ( L - K Y N ) to 3-hydroxyanthranilic acid (3-
OHAA) and anthranilic acid (AA), respectively [1]. The reac-
tion is pyridoxal-5'-phosphate (PLP) dependent and is sensi-
tive to nutritional vitamin B6 deprivation in mammals [2]. The 
biochemical properties of kynureninase were studied in 
mouse, rat and pig liver extracts [3-6] showing that this en-
zyme is an homodimer of around 95 kDa. It is present in all 
major classes of vertebrates [7] and can be regarded as a 3-
hydroxykynureninase-type enzyme, since it hydrolyzes prefer-
entially 3-OHKYN [8]. The product of this reaction, 3-OHAA 
is further utilised to synthesize quinolinic acid (QUINA), 
whose neurotoxic effect in the CNS is well documented [9]. 
On the other hand, L - K Y N can be converted by kynurenine 
aminotransferase to produce kynurenic acid (KYNA), a neu-
roprotective agent [1]. Therefore, increases in KYNA concen-
trations within the central nervous system could mitigate the 
neurotoxic effects of QUINA while reductions in KYNA lev-
els could promote excitotoxicity. Intraperitoneal injection of a 
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kynureninase inhibitor o-methoxybenzoylalanine (oMBA), in-
creases the concentration of KYNA in the hippocampal ex-
tracellular space and is able to prevent audiogenic convulsions 
in DBA/2 mice [10]. This, among other evidence [11], suggests 
that the pharmacological modulation of the kynurenine path-
way could have neuroprotective effects. A substantial increase 
in the kynureninase activity has been observed in several cer-
ebral and systemic inflammatory conditions [12]. In addition, 
it has been recently found that interferon-γ induces kynureni-
nase activity in murine macrophages [13] and kynureninase 
mRNA in human monocyte/macrophages [14]. Moreover, re-
cent in vivo data [15] suggested either the existence of two 
kynureninase enzymes or the presence of different regulatory 
co-factors of the enzymatic activity in liver and brain tissues. 
The cloning and characterization of kynureninase cDNA ex-
pression is therefore instrumental for clarifying the function of 
this enzyme, the existence of possible tissue-specific isoforms, 
the regulation of its expression by immune stimuli and its 
possible involvement in disorders associated with unbalanced 
levels of QUINA and KYNA. To gain insights into the phys-
iology and pathology of the kynurenine pathway we have 
recently isolated the cDNAs encoding two other enzymes: 
kynurenine aminotransferase [16] and kynurenine 3-hydroxyl-
ase [17]. Here we report the molecular cloning of rat and 
human kynureninase and their biochemical characterization 
in transiently transfected COS-1 cells. The constitutive expres-
sion of rat kynureninase mRNA is also demonstrated in liver, 
kidneys, brain and other tissues by reverse-transcribed poly-
merase chain reaction (RT-PCR) and Northern blot analysis. 
2. Materials and methods 
2.1. Partial amino acid sequence of rat liver kynureninase 
Rat liver kynurenmase was purified to homogeneity as previously 
described [18]. Both the intact enzyme and the protein electroblotted 
onto PDVF membrane, were subjected to Edman's degradation. Next, 
500 pmol of purified rat kynureninase were digested by trypsin and 
CNBr, and the samples were subjected to reverse-phase HPLC (col-
umn 4.6X250 mm, Biofine RPC-SC18 or YMC-c4). The resulting 
polypeptide fragments were identified and collected. Sequence analysis 
was performed by Edman's degradation in a gas-phase sequencer 
(Applied Biosystems, Foster City, CA). Several peptide sequences 
were obtained: Ml: CSYKYLNSGAGGLAGAFIHEKHAHTIK-
PALVGX; M2: FGHELSTRFNM; M3: VKTYLEELDK; M4: 
AKIGAYGHEVGKRPX; M5: IIGDESI; M6: IKPREGEETLR; 
Ml: AKIGAY; M8: KDIVGAHEKEIA; M9: EPSPLELPVDAVR-
RIATELNCDP; Tl: HAHTIKPALVGXFGHELSTR; T2: 
FNMDNK; T3: TYLEELDKXAKIGAYGHEVGK; T4: PXIIG-
DESI; T5: LDEEDKLK; T6: VAPVPLYNSFHDVYK; T7: 
LQLIPGVNGFR; T8: AFPSDHYAIEXQI; T9: DLPSIDLSLV-
NEDDNAIYFLGN; 770: SILLTGYLEYL. CNBr peptides are de-
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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noted with a prefix M, and tryptic peptides with a prefix T. Amino 
acids are named using the one-letter code. 
2.2. Rat and human kynureninase cDNA clones selection from Xgtll 
phage libraries of liver cDNA 
A 96-bp-long fragment of the rat kynureninase cDNA was obtained 
by RT-PCR as follows. Reverse transcription was performed using rat 
liver poly(A)+ mRNA, obtained using oligo (dT)-cellulose spin col-
umns (Pharmacia Biotech, Uppsala, Sweden) on total RNA, extracted 
according to the RNAzol method (Cinna/Biotex Lab, TX). Reverse 
transcription and PCR were performed as previously described 
[19,20]. Two amino acid sequences from the least degenerated regions 
of the following overlapping peptides: Ml , M2, Tl and T2, were 
selected to design degenerated oligonucleotides: 5'-GC(G,A,T,C)-
TT(T,C)AT(A,T,C)CA(T,C)GA(A,G)AA(A,G)CA-3' (sense orienta-
tion) based on the peptide sequence AFIHEKH and 5'-(T,Q-
TT(A,G)TT(A,G)TCCAT(A,G)TT(A,G)AA(G,A,C,G)C-3'(antisense 
orientation) based on the peptide sequence RFNMDNK. The product 
of the amplification was gel-purified and sequenced using the Sequen-
ase Kit (United States Biochemicals Corp., Cleveland, OH). 
Rat and human cDNA libraries were constructed starting from 1 μg 
of liver poly(A)+ mRNA in Xgtll essentially as previously described 
[21]. The 96-bp PCR product was used as a probe to screen under 
stringent conditions the rat liver Xgtll cDNA library. More than 20 
positive clones were obtained and the one with the longest insert was 
selected. The λ phage DNA was digested with R:oRI and the insert 
was purified by gel electrophoresis and subcloned into a Bluescript SK 
phagemid (Stratagene, La Jolla, CA). Sequencing was carried out with 
universal and gene specific primers. Oligonucleotides were synthesised 
using the 394 DNA/RNA Synthesizer (Applied Biosystem, Foster 
City, CA) and purified with Sephadex G25 columns (Pharmacia Bio-
tech, Uppsala, Sweden). The screening of the human liver cDNA 
library was performed using the rat full-length cDNA as 32P-labelled 
probe. The insert was cleaved from the positive human clones with 
EcoRl restriction enzyme and subcloned into a Bluescript SK vector 
(Stratagene, La Jolla, CA). 
2.3. RT-PCR study and Northern blot analysis of rat kynureninase 
mRNA expression in different tissues 
Rat poly(A)+ mRNA from different tissues (Clontech, Palo Alto, 
CA) was treated for 30 min with RNase-free DNase (Stratagene, La 
Jolla, CA) at 37°C to remove any residual genomic DNA. Messenger 
RNA samples were reverse transcribed at 37°C for 60 min. The re-
action mixture contained 250 ng of poly(A)+ mRNA, 50 mM Tris-
HC1 (pH 8.3), 75 mM KC1, 3 mM MgCl2, 4 mM DTT, 0.5 mM each 
dNTP, 30 U of RNase Inhibitor (Promega, Madison, WI), 100 pmol 
of random examers (Promega, Madison, WI) and 200 U Superscript 
Reverse Transcriptase (GIBCO Life Tech., Gaithersburg, MA), in a 
final volume of 30 μΐ. The reverse transcription step was omitted in 
PCR controls from each RNA sample to check for the presence of 
contaminating genomic DNA. Three microliters of each cDNA were 
used for the PCR reaction. The PCR mix contained 0.2 μΜ of up-
stream and downstream primers 5'-CAACTATGACTGCGCT-
GAGG-3'; 5'-GTTCTCGCTTGTCACAGACG-3', 200 μΜ of each 
dNTP, 50 mM KC1, 10 mM Tris-HCl (pH 8.3), 2 mM MgCl, 2.5 U of 
Amplitaq (Perkin Elmer Cetus, Norwalk, CT). Thermal cycling was 
performed as follows: 1 min at 94°C, 1 min at 60°C, 2 min at 72°C for 
30 cycles. For the Northern Blot analysis: a commercial filter (Clon-
tech, Palo Alto, CA) containing 2 μg per lane of poly(A)+ mRNA 
from different rat tissues was hybridised under stringent conditions 
with the 32P-labelled 96-bp PCR product used for the screening of the 
rat library. 
2.4. Recombinant expression of rat and human kynureninases in COS-1 
cells and enzymatic assays 
The rat and human kynureninase cDNAs were inserted into the 
Xhol site of the eukaryotic expression vector pSVL (Pharmacia Bio-
tech, Uppsala, Sweden). Inserts were obtained by means of PCR and 
specific 5' and 3' primers. The following oligonucleotides were used: 
5'-TGTCTCGAGCTGATGGAGCCCTCGCCT-3' (sense) and 5'-
TGTCTCGAGGGCTAGTTTCTTTCTGTAG-3' (antisense) for rat 
kynureninase; 5'-TGTCTCGAGGTAATGGAGCCTTCATCT-3' 
sense) for human kynureninase. The identity of the PCR fragments 
was verified by DNA sequencing of both strands. COS-1 cells 
(1 500000/75 cm2), grown in DMEM medium, were transfected with 
10 μg of pSVL-rat or pSVL-human kynureninase DNA using the 
calcium phosphate method [22]. Seventy-two hours after transfection, 
cells were disrupted by 4 cycles of freezing and thawing. After cen-
trifugation of the lysate (15000Xg for 30 min) the supernatant was 
stored at —20°C and used for the enzymatic assay. 
Kynureninase activity was assayed according to Kawai et al. [23]. 
The assay mixture contained 2 mM of L - K Y N or DL-30HKYN, 20 
μΜ of PLP in 50 mM Tris buffer (pH 8.5), and the reaction was 
stopped with TCA 8.3% (w/v), at different times after incubation at 
37°C and centrifuged. The supernatant was applied to a C18 reversed-
phase column (201TP54, 4.6x25 cm, Vydac Separation Group, CA) 
and eluted isocratically at a flow rate of 1 ml/min with a mobile phase 
consisting of 80 mM potassium phosphate (pH 2.5), 17% (v/v) aceto-
nitrile. AA or 3-OHAA were measured with a fluorescence detector 
on line (Waters 414, Waters Corporation, MA) set at λβΧ = 313 nm 
and Xem = 420 nm. The detection was about 60-fold less sensitive for 3-
HOAA than for AA in these experimental conditions. Kinetic con-
stants were calculated with a non-linear regression program (Sigma-
Plot) using the Michaelis-Menten equation. Notably, kynureninase 
has been shown to be specific for the L-forms of 30HKYN whereas 
the D-forms are neither substrates nor inhibitors of the enzyme [1], 
Since in this work the racemic (DL) form of 30HKYN was used, the 
reported Km values should accordingly be divided by a factor of two 
to obtain the correct Km for L-30HKYN. 
Cysteine-conjugate ß-lyase activity was measured using a coupled 
assay as described by Abraham and Cooper [24]. The reaction mix-
ture, consisting of 50 mM Tris buffer (pH 8.5), 2 mM S-(l,2-dichlor-
ovinyl)-L-cysteine (DCVC), 0.5 mM a-keto-y-methiolbutyrate, 0.1 
mM PLP, was incubated for 0, 30, 60 min prior to the incubation 
of the reaction product with 1.8 U alanine dehydrogenase with addi-
tion of 0.3 mM NADH and 0.1 M ammonium acetate. Absorbance at 
340 nm was measured using a microplate reader. All reagents were 
from Sigma if not otherwise indicated. 
3. Results and discussion 
Rat liver kynureninase was purified to homogeneity from 
the liver homogenate supernatant with a 1286-fold enrichment 
of the kynureninase activity in the final fraction [18]. N o se-
quence information could be obtained after Edman 's degra-
Table 1 
Kinetic properties of recombinant human and rat kynureninase expressed in COS-1 cells and measured in presence of 20 μΜ PLP 
Human kynureninase 
V K 



















Km were determined measuring kynureninase activity at 10 different concentrations of l-KYN (range 10 μΜ to 10 mM) and six different concen-
trations of DL-3HOKYN (range 10 μΜ to 0.5 mM). Protein concentration for rat and human kynureninase assay were 0.78 mg/ml and 0.18 mg/ml, 
respectively. 
For the rat enzyme, reaction rate was also measured in presence of o-(methoxybenzoyl)alanine (5 μΜ) with L - K Y N and D L - 3 0 H K Y N concen-
trations in the range of the Km values. 
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Fig. I. Nucleotide sequence and predicted pri~a~ amin? acid seque?ce of ~at kynurenin~se. Regions of a~ign~ent wit~ trypsin and. C~Br
cleavage fragments are underlined. The PLP binding region is underhned twice, The astensk shows the lysme mv~lved m the PLP binding,
Triplets coding for amino acids which differ from those observed by Takeuchi et al. [25] are boxed (GeneBank accession number U68168).
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dation of the purified protein, indicating that the NH2-tenni-
nus is probably modified as a result of a post-transcriptional
event. This data is in agreement with the study of Takeuchi et
al. [25] which demonstrates the presence of a N-acetylmethio-
nine at the N-terminal residue of the protein purified from rat
liver. Several peptide sequences were obtained from the puri-
fied rat kynureninase (Fig. I). Degenerated oligonucleotides
were designed from the amino acid sequences of peptides M1,
M2, T1 and T2 and they were used as primers for RT-PCR of
rat liver cDNA (see Section 2 for details). The resulting 96-bp
cDNA product was used to screen a rat liver cDNA library
and to isolate a full-length rat kynureninase cDNA clone (Fig.
1). The rat kynureninase cDNA is 1765 nucleotides long. It
contains a unique translation initiation site in position 52 and
an open reading frame coding for a protein of 464 amino acid
residues. The comparison of the rat kynureninase predicted
sequence and the primary sequence of the native protein
[25], shows two major differences: alanine instead of threonine
(residue 18) and threonine instead of serine (residue 118).
Notably, we also found an alanine residue in position 18 in
the native protein (see peptide M9 sequence). Moreover, the-
onine in position 18 was found to be modified with an un-
known group [25]. Whether these differences reflect the pres-
ence of two functionally distinct isoforms of the enzyme
deserve further investigation. The tissue distribution of rat
kynureninase mRNA was analyzed by Northern blot and
RT-PCR. Fig. 2 shows the constitutive presence in liver and
kidney, of a single kynureninase transcript, approximately 2.0
kb long. The RT-PCR analysis (Fig. 3), which is more sensi-
tive than Northern blot, shows that rat kynureninase mRNA
is also detectable in heart, retina, ovary, lung, testis and brain,
consistent with the organ distribution of the kynureninase
activity [23].
The rat kynureninase cDNA was used as probe to screen a
human liver cDNA library and to isolate a cDNA clone cor-
responding to the human kynureninase (see Section 2 for de-
tails). The rat and human kynureninase cDNAs show a 70%
identity at the nucleotide level (not shown) and 85% of iden-
tity at the protein level (Fig. 4). While this manuscript was in
preparation, the cDNA sequence of the human kynureninase
was reported [26]. No differences can be observed between the
published human kynureninase cDNA sequence [26] and the
Fig. 2. Northern blot analysis of rat kynureninase mRNA in vari-
ous rat tissues (adult Sprague-Dawley). Lanes: I, heart; 2, brain; 3,
spleen; 4. lung; 5. liver; 6, skeletal muscle; 7. kidney; 8, testis.
RNA size (kb) is shown on the left.
one we refer to. A comparison of the human kynureninase
eDNA sequence with the EST databank at NIH resulted in
the detection of several sequences (accession No. R27138,
R II 005, among others) containing either the 5' or the 3' un-
translated region of human kynureninase. These cDNA frag-
ments were obtained from placenta and liver/spleen of a male
fetus indicating the constitutive expression of the kynureni-
nase mRNA in these human tissues, Interestingly, two puta-
tive proteins (Fig. 4) predicted on the base of the Caenorhab-
ditis elegans chromosome III (accession No. U56965) and of
the Saccharomyces cerevtsiae chromosome XII (accession No.
U 19027) DNA sequence, exhibit high degree of homology
with rat and human kynureninase. In particular, the region
of the proteins containing the PLP-binding site (Lys27li in the
rat sequence): FACWCSYKY is conserved among the four
sequences (Fig. 4). Based upon sequence comparison we pro-
pose that these unidentified sequences encode S. cerevisiae and
C. elegans kynureninase.
To further confirm that the isolated cDNAs encoded rat
and human kynureninase the two cDNAs were subcloned
into the pSVL expression vector and transfected to COS-I
cells, Kynureninase and hydroxykynureninase activities were
detected in transfected COS-l cells (Table I). No activity was
observed in cells transfected with the antisense cDNAs. Table
I shows the kinetic properties of the two enzymes. Kynureni-
nase activity was measured at different concentrations of L-
KYN (from 0.01 to 10 mM), Kill values obtained for both
recombinant proteins are similar to the values published for
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the rat native [5] and human recombinant enzymes [26]. No-
tably, when DL-30HKYN was used as substrate, the kinetic of
the reaction could be considered linear only during the first
6 min of reaction. At longer reaction time we could observe a
decrease of the reaction velocity compatible, as reported for
the native enzyme [3], with an inhibitory effect of the reaction
product: 3-0HAA. With DL-30HKYN as substrate, the Kill
for both rat and human enzymes was about IO-fold lower and
the VlIl ax about S-fold higher than using L-KYN. The rat
kynureninase and hydroxykynureninase activities were inhib-
ited by oMBA [10], a competitive inhibitor of kynureninase,
with a half-maximal inhibitory value of 2.4 11M (L-KYN) and
13 11M (DL-30HK YN) respectively. Optimum pH was found
to be around 9.0 for both rat and human kynureninase using
[-KYN and around 8.5 with DL-30HKYN confirming the
property of the native protein [7].
A major route of detoxication for many halogenated xeno-
biotics is by conjugation to the tripeptide glutathione. Subse-
quent metabolic processing of such conjugates yields the cys-
teine conjugate of the original chemicals, which then may
serve as substrate for enzymes that express ~-Iyase activity.
Recently, attention has been directed toward the toxicological
importance of these enzymes because ~-Iyase action can yield
toxic metabolites [27]. The PLP-binding site of rat kynureni-
nase (Fig. I) is similar to the one present in the y family of
PLP-dependent enzymes, which contains proteins with ~-lyase
activity [25]. Notably, COS-I cells transfected with the rat
kynureninase cDNA showed a cysteine-conjugate ~-Iyase spe-
cific activity of 1.97 nmol min-I mg" using DCVC as sub-
strate. No activity was present in cells transfected with the
antisense cDNA. Fig. 4 shows that the four polypeptide se-
quences contain an almost identical PLP-binding site region.
Being this region common also to aminotransferases with cys-
teine conjugate ~-lyase activity, it is likely that also human,
and putative S. cerevisiae and C. elegans kynureninases posses
such an enzymatic activity. Apart from kidney, ~-Iyase activ-
ity is also found predominantly in the liver. As shown in Fig.
2, these are the tissues with higher levels of kynureninase
mRNA. Cysteine S-conjugates readily cross the blood-brain
barrier [28]. Inactivation of kynureninase in the brain by cys-
teine S-conjugates could therefore profoundly affect the cere-
bral level of kynurenine and its neurotoxic/neuroprotective
metabolites.
Chiarugi and coworkers investigated the effect of oMBA on
kynurenine metabolism in vivo [15]. As expected, oMBA sig-
nificantly decreased the brain content of AA, the product of
kynureninase activity. Unexpectedly, brain content of 3-
OHAA, the product of hydroxykynureninase, was not modi-
fied by the treatment. Moreover, in vitro inhibition studies
with oMBA indicated different IC"o values when enzyme
Fig. 3. RT-PCR analysis of rat kynureninase mRNA in different rat tissues (adult Sprague-Dawley). Lanes: I, negative control; 2, brain;
3, heart; 4, retina; 5, testis; 6, ovary; 7, liver; 8, lung; 9. kidney. PCR products were electrophoresed on 2'X, agarose gel, blotted into nitrocel-
lulose membrane and hybridized with 5'-end-p:12 labelled oligonucleotide: 5'-TCTCCGCTTGGATGAGGAAGAT-3',. Southern Blot results are
shown. This a qualitative assay and the relative amount of the PCR products obtained cannot be compared among different tissues.
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Fig. 4. Alignment of the rat and human kynureninase primary amino acid sequences with the predicted sequence of two putative proteins:
L808J.14 and C15H9.7 obtained from the Saccharomvces rrrcvisiac chromosome XII and the Coenorabditis elegans chromosome III,
respectively. rlkynasc, rat kynureninase ; hlkvnase, human kynurcninase. Conserved amino acids among all proteins are shaded.
preparation from liver and brain tissues where used. This
would suggests either the existence of two kynureninase en-
zymes or the presence of different enzyme modulators in pe-
ripheral and brain tissues. Our data clearly demonstrate that
the isolated liver eDNA, when transfected to COS-l cells,
possess both kynureninase and hydroxykynureninase activ-
ities. However, we cannot exclude the presence of brain-spe-
cific kynureninase isoform(s) displaying different substrate
specificity. This study analyses the molecular and biochemical
properties of rat and human liver kynureninases providing an
10
initial step to understand the pathophysiological role of this
enzyme and to design more specific inhibitors with neuropro-
tective potential.
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